Across Cancer Types, Trispecific Antibodies Show Promise in Early Result

Treatment Initiation and Supportive Care Processes

Panelists discuss how preparing multiple myeloma patients for treatment involves structured education, emotional support, and proactive symptom management—emphasizing clear communication about the four-drug regimen, logistics, and supportive care to empower patients and ensure safety throughout their treatment journey.

Across Cancer Types, Trispecific Antibodies Show Promise in Early Result

Innovative trispecific antibodies show promise in treating relapsed/refractory multiple myeloma and neuroendocrine carcinoma, enhancing patient outcomes and safety.

Advanced Practice Decision-Making: Patient Selection and Baseline Assessment for Bispecific Therapies

Panelists discuss the evolving role of bispecific antibodies in relapsed/refractory multiple myeloma, emphasizing their value as off-the-shelf options for patients post chimeric antigen receptor T-cell therapy or ineligible for it, and highlighting personalized treatment decisions based on prior therapies, antigen targets, infection risk, and emerging clinical evidence.

A Potential Turning Point: CAR T-Cell Therapy Shows Long-Term Survival in Advanced Multiple Myeloma – Patient Worthy

At the recent American Society of Clinical Oncology (ASCO) annual meeting, researchers unveiled remarkable long-term results for ciltacabtagene autoleucel (cilta-cel; Carvykti), a CAR T-cell therapy, in patients with heavily pretreated relapsed or refractory multiple myeloma. The findings from a post-hoc analysis of the CARTITUDE-1 trial suggest that, for some, a single infusion of cilta-cel may […]

Identifying High-Risk Multiple Myeloma

(MedPage Today) — While the introduction of novel therapies has led to substantial improvements in the outcomes of patients with newly diagnosed multiple myeloma, there remains a high-risk population of patients who experience early disease progression… Source link : https://www.medpagetoday.com/spotlight/asco-mm/116504 Author : Publish date : 2025-07-15 15:11:00 Copyright for syndicated content belongs to the linked […] The post Identifying Hig…